210 related articles for article (PubMed ID: 35728507)
1. Recent advances in the development of EGFR degraders: PROTACs and LYTACs.
Hong D; Zhou B; Zhang B; Ren H; Zhu L; Zheng G; Ge M; Ge J
Eur J Med Chem; 2022 Sep; 239():114533. PubMed ID: 35728507
[TBL] [Abstract][Full Text] [Related]
2. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor PROTACs as an effective strategy for cancer therapy: A review.
Wang C; Zhang Y; Chen W; Wang Y; Xing D
Biochim Biophys Acta Rev Cancer; 2023 Jul; 1878(4):188927. PubMed ID: 37245798
[TBL] [Abstract][Full Text] [Related]
4. The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders.
Li P; Li B; Yang N; Xu T; Zheng Z
Expert Opin Ther Pat; 2023; 33(7-8):477-492. PubMed ID: 37873645
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands.
Zhao HY; Wang HP; Mao YZ; Zhang H; Xin M; Xi XX; Lei H; Mao S; Li DH; Zhang SQ
J Med Chem; 2022 Mar; 65(6):4709-4726. PubMed ID: 35254067
[TBL] [Abstract][Full Text] [Related]
6. Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide.
He K; Zhang Z; Wang W; Zheng X; Wang X; Zhang X
Bioorg Med Chem Lett; 2020 Jun; 30(12):127167. PubMed ID: 32317208
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.
Shi S; Du Y; Huang L; Cui J; Niu J; Xu Y; Zhu Q
Bioorg Chem; 2022 Mar; 120():105605. PubMed ID: 35081479
[TBL] [Abstract][Full Text] [Related]
8. Exploring Degradation of Mutant and Wild-Type Epidermal Growth Factor Receptors Induced by Proteolysis-Targeting Chimeras.
Yu X; Cheng M; Lu K; Shen Y; Zhong Y; Liu J; Xiong Y; Jin J
J Med Chem; 2022 Jun; 65(12):8416-8443. PubMed ID: 35675209
[TBL] [Abstract][Full Text] [Related]
9. Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy.
Fang Y; Wang J; Zhao M; Zheng Q; Ren C; Wang Y; Zhang J
J Med Chem; 2022 Sep; 65(17):11454-11477. PubMed ID: 36006861
[TBL] [Abstract][Full Text] [Related]
10. Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities.
Maity P; Chatterjee J; Patil KT; Arora S; Katiyar MK; Kumar M; Samarbakhsh A; Joshi G; Bhutani P; Chugh M; Gavande NS; Kumar R
J Med Chem; 2023 Mar; 66(5):3135-3172. PubMed ID: 36812395
[TBL] [Abstract][Full Text] [Related]
11. Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs.
Alabi SB; Crews CM
J Biol Chem; 2021; 296():100647. PubMed ID: 33839157
[TBL] [Abstract][Full Text] [Related]
12. Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC).
Zhang H; Zhao HY; Xi XX; Liu YJ; Xin M; Mao S; Zhang JJ; Lu AX; Zhang SQ
Eur J Med Chem; 2020 Mar; 189():112061. PubMed ID: 31951960
[TBL] [Abstract][Full Text] [Related]
13. Discovery of highly potent and selective CRBN-recruiting EGFR
Zhang W; Li P; Sun S; Jia C; Yang N; Zhuang X; Zheng Z; Li S
Eur J Med Chem; 2022 Aug; 238():114509. PubMed ID: 35691176
[TBL] [Abstract][Full Text] [Related]
14. Progress of small molecules for targeted protein degradation: PROTACs and other technologies.
Zhao HY; Xin M; Zhang SQ
Drug Dev Res; 2023 Apr; 84(2):337-394. PubMed ID: 36606428
[TBL] [Abstract][Full Text] [Related]
15. New Frontiers in the Discovery and Development of PROTACs.
Barghout SH
Anticancer Agents Med Chem; 2022 Aug; 22(15):2656-2661. PubMed ID: 35418290
[TBL] [Abstract][Full Text] [Related]
16. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
Zhang C; Han XR; Yang X; Jiang B; Liu J; Xiong Y; Jin J
Eur J Med Chem; 2018 May; 151():304-314. PubMed ID: 29627725
[TBL] [Abstract][Full Text] [Related]
17. Major Advances in Emerging Degrader Technologies.
Luo H; Wu L; He Y; Qin C; Tang X
Front Cell Dev Biol; 2022; 10():921958. PubMed ID: 35813205
[TBL] [Abstract][Full Text] [Related]
18. Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation.
Yan J; Li T; Miao Z; Wang P; Sheng C; Zhuang C
J Med Chem; 2022 Jul; 65(13):8798-8827. PubMed ID: 35763424
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab-based PROteolysis targeting chimera for effectual downregulation of NSCLC with varied EGFR mutations.
Vartak R; Deore B; Sanhueza CA; Patel K
Int J Biol Macromol; 2023 Dec; 252():126413. PubMed ID: 37598823
[TBL] [Abstract][Full Text] [Related]
20. The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation.
He J; Zhou Z; Sun X; Yang Z; Zheng P; Xu S; Zhu W
Eur J Med Chem; 2021 Jan; 210():112995. PubMed ID: 33243531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
